Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Freshworks Q3 Adjusted Earnings, Revenue Rise; Updates 2026 Guidance

Freshworks Q3 Adjusted Earnings, Revenue Rise; Updates 2026 Guidance

MT newswireMT newswire2026/11/03 21:24
05:24 PM EST, 11/03/2026 (MT Newswires) -- Freshworks (FRSH) reported Q3 adjusted earnings late Tuesday of $0.22 per diluted share, up from $0.16 a year earlier. Analysts polled by FactSet expected $0.18. Revenue for the quarter ended Sept. 30 was $245.4 million, up from $215.1 million a year earlier. Analysts expected $245.1 million. The company expects Q4 adjusted EPS of approximately $0.21 on revenue of $253.5 million to $254.5 million. Analysts expect $0.21 and $253.9 million, respectively. The company now expects 2026 adjusted EPS of approximately $0.71 on revenue of $965 million to $966 million. It previously expected adjusted EPS of $0.66 to $0.68 on revenue of $963.5 million to $966.5 million. Analysts expect $0.67 and $965 million, respectively. Freshworks shares fell 5% in after-hours trading.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss